Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.
The specificity, toxicity, and efficacy of alpha-particle-mediated radioimmunotherapy of murine erythroleukemia was assessed by use of tumor-specific monoclonal antibody 103A labeled with 212Bi. Forty % of the injected dose/g tissue targeted to neoplastic spleens within 1 h after i.v. injection. When 212Bi-103A was injected on day 13 of disease, a dose-dependent response was achieved, as measured by a reduction in splenomegaly and absence of liver metastasis. Mice treated with 212Bi-103A on day 8 of disease showed no histological evidence of erythroleukemia on day 22 and survived significantly longer (median, 118 days) than mice treated with 212Bi-control IgG (78 days) or untreated mice (63 days), indicating successful specific radioimmunotherapy.
Huneke
R B
RB
Department of Comparative Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Pippin
C G
CG
Squire
R A
RA
Brechbiel
M W
MW
Gansow
O A
OA
Strand
M
M
D000512:Alpha Particles / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001729:Bismuth / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002417:Cattle; D007074:Immunoglobulin G / Q000627:therapeutic use; D051379:Mice; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011925:Rauscher Virus
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D011868:Radioisotopes; D001729:Bismuth